Notice to Contributors

Manuscripts should be sent in triplicate (original plus two copies) to the Editor, Dr. Michael Moore. The criteria for acceptance of manuscripts to be published in the British Journal of Cancer are originality and high scientific quality. Manuscripts are accepted on the understanding that they report unpublished work that is not under consideration for publication elsewhere, that all named authors have agreed to its submission and that if accepted it will not be published in the same form, in any language, without the consent of the Publishers. Papers should be in English. Authors whose mother-tongue is not English are urgently requested to have their manuscripts checked for linguistic correctness before submission.

Manuscripts should be typewritten, double-spaced with a wide margin and on one side of the paper only. They should be accompanied by a title page numbered as 1, bearing title, authors full names, affiliation and addresses; and a summary of not more than 200 words. The author to whom correspondence, proofs and reprint requests are to be sent should be clearly indicated.

Full papers should be divided into sections:
1. Introduction
2. Materials and methods
3. Results
4. Discussion
5. Acknowledgements and References.
Short Communications (~1500 words) should not have the above section headings nor a summary. The Editor reserves the right to make literary corrections.

Titles. These are the most read part of papers. Authors should compose them with great care. They should combine brevity with clarity; the shorter the better, not exceeding 100 letters. Authors should submit their own running title, which must not exceed 50 letters. The top of each page should carry the running title and the name of the first author.

Illustrations should be referred to in the text as “Figures” and be given Arabic numbers. They should be marked on the back with the authors name(s) and the title of the paper. Where there is any possible doubt as to the orientation of an illustration, the top should be indicated by an arrow. Photographs and photomicrographs should be high-quality unmounted glossy prints and should not be retouched. Magnification is best indicated by a line representing a defined length, included within the photograph. Colour illustrations will be accepted when found necessary by the Editor, although the author will be expected to contribute to the cost. Diagrams should be on separate sheets; they must be drawn with black Indian ink on white paper or feint-ruled graph paper and should be about twice the size of the final reproduction. Lines should be of sufficient thickness to stand reduction. Photocopies are unacceptable. Each illustration should be clearly described by a legend; all legends should be grouped on a separate sheet of paper. Lettering on figures should be minimal and should not duplicate the legend.

There should be as few Tables as possible; they should have a title and include only essential data; they should be typewritten on separate sheets and given Roman numbers.

References. Only papers closely related to the author’s work should be quoted, and these should be to original papers only. Exhaustive lists should be avoided.† References in the text should be made by giving the author’s surname, with the year of publication in brackets. When the reference is to a specific part of a book, the page number should also be cited. When reference is made to a work by 3 or more authors, the first name followed by et al. should be used on all occasions. If several papers by the same first author and from the same year are cited, a, b, c, etc. should be added after the year of publication. It is the author’s responsibility to check the accuracy of all references before submitting a manuscript. References should be brought together at the end of the paper in alphabetical order, where titles of papers and all authors’ names should be given in full (except if there are more than 6 authors, when the first 3 names should be followed by “and x others”, x being the actual number). Names of journals should be abbreviated as in the Index Medicus, but with full stops after abbreviations (and after authors’ initials), followed by the volume number and the page number, e.g.:


References to books and monographs should appear as in the following examples:


Abbreviations and units should follow the standards laid down in Units, Symbols and Abbreviations published by the Royal Society of Medicine (third edition, 1977).

Offprints may be ordered on the form accompanying proofs; 25 will be supplied free of charge.

*Editorial correspondence should be addressed to the Editor, Dr Michael Moore, Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester M20 9BX.

†Citation of Conference Proceeding or Meetings Abstracts should be avoided unless there is no other reference.
FORTHCOMING PAPERS IN THE SEPTEMBER ISSUE
OF THE BRITISH JOURNAL OF CANCER

Volume 48, No. 3 September 1983


FORMAN, D., DOLL, R. AND PETO, R. Trends in normality from carcinoma of the liver and the use of oral contraceptives.


JOYCE, R.M. AND VINCENT, P.C. Advantage of reduced oxygen tension in growth of human melanomas in semi-solid cultures: Quantitative analysis.


MATTHEWS, N. Anti-tumour cytotoxin produced by human monocytes: Studies on its mode of action.

VILLA, M.L., MIGLIOI, M. AND CLERICI, E. Antibody production in cultured blood lymphocytes from breast cancer patients.


NIRMUL, D., PEGORARO, R.J., JIALAL, I., NAIDOO, C. AND JOUBERT, S.M. The sex hormone profile of male patients with breast cancer.


BISHOP, C.J. AND WHITING, V.A. The role of natural killer cells in intravascular death of intravenously injected murine tumour cells.

CLUTTERBUCK, R.D., MILLAR, J.L. AND ALEXANDER, P. Failure of high doses of α Interferon to affect the growth of human carcinoma, melanoma and myeloid leukaemia xenografts.
When the quality of life is the primary concern.

In patients with advanced malignant disease usually one instillation of Coparvax is sufficient to relieve the distressing symptoms of malignant effusions, and prevent their recurrence.

Serious side-effects are uncommon. Narcotic analgesia is not normally required.

Coparvax helps improve the quality of life.

Prescribing information. Presentation Vial containing 7 mg (dry weight of the inactivated Corynebacterium parvum organisms WFL strain CN6134) with thiomersal and glycine, in a freeze-dried form.

Uses A alleviation of malignant pleural effusions and malignant ascites. Dosage 7-14 mg is recommended, although some patients have responded to lower doses. Administration Freeze-dried Coparvax should be reconstituted with 1 ml of physiological saline for injection and diluted in a further volume of 10-20 ml prior to injection. The suspension should be injected, within 24 hours of reconstitution, into the pleural or peritoneal cavity via the paracentesis needle immediately after the effusion has been aspirated. Injection may be repeated, if necessary, at intervals of one to four weeks.

Contra-indications There are no specific contra-indications.

Precautions The incidence and severity of side-effects attributable to Coparvax administered intrapleurally appears to be intensified if given within 10 days of thoracotomy and lung resection probably due to enhanced systemic absorption of Coparvax. Coparvax should not be given during the immediate post-operative period. Following intrapleural or intra-abdominal administration, leakage of Coparvax into subcutaneous tissues may result in local tenderness. Intense fibrous reaction in the pleural and peritoneal cavities has been observed following local administration of Coparvax. Intestinal obstruction due to the formation of adhesions is a theoretical possibility, although it has not been reported as a complication of Coparvax administration. Adverse effects Fever occurs in up to 60% of patients following intracavitary injection. Abdominal pain or mild abdominal discomfort has been reported in some patients following intraperitoneal instillation. Nausea and vomiting may occur in a minority of patients following intracavitary administration of Coparvax.

Use in pregnancy Since there are no laboratory or clinical data on mutagenicity or teratogenicity Coparvax should not be administered during pregnancy. Basic NHS cost Single vial (7 mg) £33 (PL3/0097).

Further information is available on request. Calmic Medical Division, The Welcome Foundation Ltd. Crewe, Cheshire *Trade Mark.
Molecular Aspects of Anti-cancer Drug Action

Edited by Stephen Neidle, Dept. of Biophysics, King's College, London
Michael J. Waring, Dept. of Pharmacology, University of Cambridge
Volume 3 in the Topics in Molecular and Structural Biology Series.
Series editors: Watson Fuller & Stephen Neidle

August 1983; c£45.00; c405pp; ISBN 0 333 31556 1

Up-to-date information from a distinguished list of contributors for all Molecular Biologists, Pharmacologists and those involved in cancer research.

The theme of this book centres around the long-held belief that a rational approach to chemotherapy is most likely to result from a detailed understanding of the action of existing drugs at a molecular level.

Contents:

Other Titles in the Series Published: Neidle: Topics in Nucleic Acid Structure; Neidle: Topics in Nucleic Acid Structure—Part 2.

Please send orders and requests for information to:
Felicity Parker, Product Manager, Scientific and Medical Division.
The Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS, UK